Claudlo Bucolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4731598/publications.pdf

Version: 2024-02-01

186 papers 7,494 citations

43 h-index 71 g-index

188 all docs

188 docs citations

188 times ranked 8760 citing authors

#	Article	IF	CITATIONS
1	Role of Omega-3 Fatty Acids in the Treatment of Depressive Disorders: A Comprehensive Meta-Analysis of Randomized Clinical Trials. PLoS ONE, 2014, 9, e96905.	2.5	358
2	Eudragit RS100 \hat{A}^{\odot} nanosuspensions for the ophthalmic controlled delivery of ibuprofen. European Journal of Pharmaceutical Sciences, 2002, 16, 53-61.	4.0	298
3	Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 2002, 23, 3247-3255.	11.4	231
4	Omega-3 Fatty Acids and Depression: Scientific Evidence and Biological Mechanisms. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-16.	4.0	215
5	Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacological Research, 2013, 76, 132-148.	7.1	150
6	Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharmaceutical Research, 2003, 20, 584-590.	3 . 5	149
7	Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Biochemical Pharmacology, 2012, 84, 88-92.	4.4	126
8	Systemic Omega-6 Essential Fatty Acid Treatment and PGE ₁ Tear Content in Sjol^gren's Syndrome Patients. , 2005, 46, 4474.		115
9	Dopamine D3 receptor as a new pharmacological target for the treatment of depression. European Journal of Pharmacology, 2013, 719, 25-33.	3 . 5	115
10	Retinal and circulating mi <scp>RNA</scp> expression patterns in diabetic retinopathy: An in silico and in vivo approach. British Journal of Pharmacology, 2019, 176, 2179-2194.	5 . 4	104
11	The PKCβ/HuR/VEGF pathway in diabetic retinopathy. Biochemical Pharmacology, 2010, 80, 1230-1237.	4.4	95
12	Ocular drug delivery: a clue from nanotechnology. Frontiers in Pharmacology, 2012, 3, 188.	3 . 5	94
13	Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. Frontiers in Pharmacology, 2017, 8, 168.	3. 5	90
14	Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. International Journal of Pharmaceutics, 2013, 440, 135-140.	5. 2	89
15	Preparation and characterization of Eudragit Retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech, 2006, 7, E192-E198.	3.3	87
16	Current drug treatments targeting dopamine D3 receptor., 2016, 165, 164-177.		87
17	Dopamine outside the brain: The eye, cardiovascular system and endocrine pancreas., 2019, 203, 107392.		86
18	Ocular Tolerability and In Vivo Bioavailability of Poly(ethylene glycol) (PEG)â€Coated Polyethylâ€2â€Cyanoacrylate Nanosphereâ€Encapsulated Acyclovir. Journal of Pharmaceutical Sciences, 2001, 90, 288-297.	3.3	84

#	Article	IF	CITATIONS
19	Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacological Research, 2016, 111, 713-720.	7.1	84
20	Ocular Tolerability of Eudragit RS100® and RL100® Nanosuspensions as Carriers for Ophthalmic Controlled Drug Delivery. Journal of Pharmaceutical Sciences, 2002, 91, 2636-2641.	3.3	80
21	Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. International Journal of Molecular Sciences, 2020, 21, 776.	4.1	77
22	Enhanced Ocular Anti-Inflammatory Activity of Ibuprofen Carried by an Eudragit RS100 [®] Nanoparticle Suspension. Ophthalmic Research, 2002, 34, 319-323.	1.9	75
23	Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies. Journal of Pharmacological Sciences, 2018, 138, 219-232.	2.5	74
24	Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Frontiers in Pharmacology, 2015, 6, 248.	3.5	73
25	Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. International Journal of Pharmaceutics, 2014, 470, 133-140.	5.2	72
26	Case Report: Central Retinal Artery Occlusion in a COVID-19 Patient. Frontiers in Pharmacology, 2020, 11, 588384.	3.5	72
27	Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. International Journal of Pharmaceutics, 2015, 478, 180-186.	5.2	71
28	P2X7 receptor antagonism: Implications in diabetic retinopathy. Biochemical Pharmacology, 2017, 138, 130-139.	4.4	71
29	Prognostic significance of deregulated microRNAs in uveal melanomas. Molecular Medicine Reports, 2019, 19, 2599-2610.	2.4	69
30	Role of phospholipases A2 in diabetic retinopathy: In vitro and in vivo studies. Biochemical Pharmacology, 2013, 86, 1603-1613.	4.4	67
31	Pharmacological management of ocular hypertension: current approaches and future prospective. Current Opinion in Pharmacology, 2013, 13, 50-55.	3.5	66
32	Nrf2 activators modulate oxidative stress responses and bioenergetic profiles of human retinal epithelial cells cultured in normal or high glucose conditions. Pharmacological Research, 2015, 99, 296-307.	7.1	65
33	Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2â€mediated activation of the Nrf2/HOâ€1 pathway. Journal of Cellular Physiology, 2019, 234, 17295-17304.	4.1	65
34	Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits. Biomaterials, 2001, 22, 195-200.	11.4	63
35	Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway. Biochemical Pharmacology, 2015, 96, 278-287.	4.4	63
36	Homology Modeling of Dopamine D2 and D3 Receptors: Molecular Dynamics Refinement and Docking Evaluation. PLoS ONE, 2012, 7, e44316.	2.5	62

#	Article	IF	CITATIONS
37	Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats. Peptides, 2012, 37, 32-39.	2.4	59
38	Low levels of 17-β-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a case–control study. British Journal of Ophthalmology, 2014, 98, 371-376.	3.9	58
39	In Vivo Ocular Efficacy Profile of Mapracorat, a Novel Selective Glucocorticoid Receptor Agonist, in Rabbit Models of Ocular Disease., 2011, 52, 1422.		57
40	Aflibercept regulates retinal inflammation elicited by high glucose via the PIGF/ERK pathway. Biochemical Pharmacology, 2019, 168, 341-351.	4.4	57
41	Novel polysaccharides-based viscoelastic formulations for ophthalmic surgery: Rheological characterization. Biomaterials, 2006, 27, 5134-5142.	11.4	56
42	Protective Effects of a Coumarin Derivative in Diabetic Rats. , 2009, 50, 3846.		56
43	Carnosine Decreases PMA-Induced Oxidative Stress and Inflammation in Murine Macrophages. Antioxidants, 2019, 8, 281.	5.1	56
44	PACAP Modulates Expression of Hypoxia-Inducible Factors in Streptozotocin-Induced Diabetic Rat Retina. Journal of Molecular Neuroscience, 2015, 57, 501-509.	2.3	55
45	Sigma receptor ligands protect human retinal cells against oxidative stress. NeuroReport, 2006, 17, 287-291.	1.2	54
46	A New Human Blood–Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes. International Journal of Molecular Sciences, 2020, 21, 1636.	4.1	54
47	Carbon monoxide and the eye: Implications for glaucoma therapy. , 2011, 130, 191-201.		52
48	Dopamine D3 Receptor Is Necessary for Ethanol Consumption: An Approach with Buspirone. Neuropsychopharmacology, 2014, 39, 2017-2028.	5 . 4	52
49	Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. Journal of Clinical Medicine, 2020, 9, 1522.	2.4	52
50	Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. Journal of Pharmacy and Pharmacology, 2010, 56, 841-846.	2.4	49
51	Characterization and In-vivo Ocular Absorption of Liposome-encapsulated Acyclovir. Journal of Pharmacy and Pharmacology, 2010, 51, 565-576.	2.4	49
52	Effects of neurosteroids on ischemia $\hat{\epsilon}$ "reperfusion injury in the rat retina: role of $\hat{l}f1$ recognition sites. European Journal of Pharmacology, 2004, 498, 111-114.	3.5	47
53	The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. PLoS ONE, 2019, 14, e0211005.	2.5	44
54	Computational systems biology approach to identify novel pharmacological targets for diabetic retinopathy. Biochemical Pharmacology, 2018, 158, 13-26.	4.4	43

#	Article	IF	CITATIONS
55	Hyaluronan-Induced Stimulation of Corneal Wound Healing is a Pure Pharmacological Effect. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 548-553.	1.4	42
56	Sulodexide prevents activation of the PLA2/COX-2/VEGF inflammatory pathway in human retinal endothelial cells by blocking the effect of AGE/RAGE. Biochemical Pharmacology, 2017, 142, 145-154.	4.4	42
57	The immune system on the TRAIL of Alzheimer's disease. Journal of Neuroinflammation, 2020, 17, 298.	7.2	42
58	A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice. Neurobiology of Stress, 2021, 14, 100286.	4.0	42
59	Homocysteine Serum Levels in Diabetic Patients with Non Proliferative, Proliferative and without Retinopathy. BioMed Research International, 2014, 2014, 1-4.	1.9	40
60	MicroRNA target prediction in glaucoma. Progress in Brain Research, 2015, 220, 217-240.	1.4	40
61	Fortified Extract of Red Berry, <i>Ginkgo biloba </i> , and White Willow Bark in Experimental Early Diabetic Retinopathy. Journal of Diabetes Research, 2013, 2013, 1-6.	2.3	39
62	TGF- \hat{l}^21 prevents rat retinal insult induced by amyloid- \hat{l}^2 ($1\hat{a}$ €"42) oligomers. European Journal of Pharmacology, 2016, 787, 72-77.	3.5	39
63	Blood-retinal barrier protection against high glucose damage: The role of P2X7 receptor. Biochemical Pharmacology, 2019, 168, 249-258.	4.4	39
64	Chitinase Levels in the Tears of Subjects With Ocular Allergies. Cornea, 2008, 27, 168-173.	1.7	38
65	Folate status in type 2 diabetic patients with and without retinopathy. Clinical Ophthalmology, 2015, 9, 1437.	1.8	37
66	Effects of Novel Nitric Oxide-Releasing Molecules against Oxidative Stress on Retinal Pigmented Epithelial Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	37
67	POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPICAL ANTIBIOTIC PROPHYLAXIS. Retina, 2018, 38, 01-11.	1.7	37
68	Novel Therapeutics in Glaucoma Management. Current Neuropharmacology, 2018, 16, 978-992.	2.9	37
69	Different Retinal Expression Patterns of IL- \hat{l}_{\pm} , IL- \hat{l}_{2} , and Their Receptors in a Rat Model of Type 1 STZ-Induced Diabetes. Journal of Molecular Neuroscience, 2015, 56, 431-439.	2.3	36
70	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	4.4	36
71	Nap Interferes with Hypoxia-Inducible Factors and VEGF Expression in Retina of Diabetic Rats. Journal of Molecular Neuroscience, 2017, 61, 256-266.	2.3	35
72	Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery. Frontiers in Pharmacology, 2018, 9, 285.	3.5	35

#	Article	IF	CITATIONS
73	Activation of the VEGF-A/ERK/PLA2 Axis Mediates Early Retinal Endothelial Cell Damage Induced by High Glucose: New Insight from an In Vitro Model of Diabetic Retinopathy. International Journal of Molecular Sciences, 2020, 21, 7528.	4.1	35
74	TGF- \hat{l}^2 Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy. International Journal of Molecular Sciences, 2020, 21, 9558.	4.1	35
75	Effect of chitinase inhibitors on endotoxin-induced uveitis (EIU) in rabbits. Pharmacological Research, 2008, 57, 247-252.	7.1	34
76	When nanotechnology meets the ocular surface. Expert Review of Ophthalmology, 2008, 3, 325-332.	0.6	34
77	Acidic Mammalian Chitinase in Dry Eye Conditions. Cornea, 2009, 28, 667-672.	1.7	34
78	Topical Ocular Delivery of TGF- $\hat{1}^21$ to the Back of the Eye: Implications in Age-Related Neurodegenerative Diseases. International Journal of Molecular Sciences, 2017, 18, 2076.	4.1	34
79	Retinal Protection and Distribution of Curcumin in Vitro and in Vivo. Frontiers in Pharmacology, 2018, 9, 670.	3.5	34
80	P2X7 receptor antagonism preserves retinal ganglion cells in glaucomatous mice. Biochemical Pharmacology, 2020, 180, 114199.	4.4	34
81	Contribution of $\hat{l}\pm4\hat{l}^21$ integrin to the antiallergic effect of levocabastine. Biochemical Pharmacology, 2008, 76, 751-762.	4.4	33
82	Modulation of IL-1 \hat{l}^2 and VEGF expression in rat diabetic retinopathy after PACAP administration. Peptides, 2017, 97, 64-69.	2.4	33
83	Protective effect of PACAP-38 on retinal pigmented epithelium in an in vitro and in vivo model of diabetic retinopathy through EGFR-dependent mechanism. Peptides, 2019, 119, 170108.	2.4	33
84	Resolvin D1 Modulates the Intracellular VEGF-Related miRNAs of Retinal Photoreceptors Challenged With High Glucose. Frontiers in Pharmacology, 2020, 11, 235.	3 . 5	33
85	Influence of Trace Elements on Neurodegenerative Diseases of The Eyeâ€"The Glaucoma Model. International Journal of Molecular Sciences, 2021, 22, 4323.	4.1	33
86	The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß 1-42 oligomers in mice. Pharmacological Research, 2016, 106, 10-20.	7.1	32
87	Stabilization of HIF-1α in Human Retinal Endothelial Cells Modulates Expression of miRNAs and Proangiogenic Growth Factors. Frontiers in Pharmacology, 2020, 11, 1063.	3.5	32
88	Ocular Formulation Based on Palmitoylethanolamide-Loaded Nanostructured Lipid Carriers: Technological and Pharmacological Profile. Nanomaterials, 2020, 10, 287.	4.1	32
89	Controversies in Glaucoma: Current Medical Treatment and Drug Development. Current Pharmaceutical Design, 2015, 21, 4673-4681.	1.9	32
90	Davunetide (NAP) Protects the Retina Against Early Diabetic Injury by Reducing Apoptotic Death. Journal of Molecular Neuroscience, 2014, 54, 395-404.	2.3	31

#	Article	IF	CITATIONS
91	Topical Application of a Nitric Oxide Synthase Inhibitor Reduces Intraocular Pressure in Rabbits with Experimental Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2003, 19, 527-534.	1.4	30
92	Antioxidant and Osmoprotecting Activity of Taurine in Dry Eye Models. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 188-194.	1.4	30
93	Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage. Frontiers in Pharmacology, 2021, 12, 705405.	3.5	30
94	MicroRNAs in the Vitreous Humor of Patients with Retinal Detachment and a Different Grading of Proliferative Vitreoretinopathy: A Pilot Study. Translational Vision Science and Technology, 2020, 9, 23.	2.2	30
95	Protective effects of the sigma agonist Pre-084 in the rat retina. British Journal of Ophthalmology, 2007, 91, 1382-1384.	3.9	29
96	Gabapentin Attenuates Ocular Inflammation: In vitro and In vivo Studies. Frontiers in Pharmacology, 2017, 8, 173.	3.5	29
97	Ocular Hypotensive Action of Topical Flunarizine in the Rabbit: Role of Ï,1 Recognition Sites. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 1086-1094.	2.5	28
98	Dopamine-3 receptor modulates intraocular pressure: Implications for glaucoma. Biochemical Pharmacology, 2012, 83, 680-686.	4.4	28
99	Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. European Neuropsychopharmacology, 2015, 25, 1427-1436.	0.7	28
100	Novel ophthalmic formulation of myriocin: implications in retinitis pigmentosa. Drug Delivery, 2019, 26, 237-243.	5.7	28
101	Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease. Frontiers in Pharmacology, 2019, 10, 1240.	3.5	27
102	Novel indole derivatives targeting HuR-mRNA complex to counteract high glucose damage in retinal endothelial cells. Biochemical Pharmacology, 2020, 175, 113908.	4.4	27
103	Carnosine Protects Macrophages against the Toxicity of AÎ 2 1-42 Oligomers by Decreasing Oxidative Stress. Biomedicines, 2021, 9, 477.	3.2	27
104	Rapid determination of nimesulide in rabbit aqueous humor by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 804, 441-443.	2.3	26
105	Acidic Mammalian Chitinase and the Eye: Implications for Ocular Inflammatory Diseases. Frontiers in Pharmacology, 2011, 2, 43.	3.5	26
106	Regulation of vascular tone in rabbit ophthalmic artery: Cross talk of endogenous and exogenous gas mediators. Biochemical Pharmacology, 2014, 92, 661-668.	4.4	26
107	Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammationâ€. Journal of Pharmacy and Pharmacology, 2014, 66, 954-960.	2.4	25
108	Pericyte-like differentiation of human adipose-derived mesenchymal stem cells: An <i>in vitro</i> study. World Journal of Stem Cells, 2020, 12, 1152-1170.	2.8	25

#	Article	IF	Citations
109	Effects of Cloricromene, a Coumarin Derivative, on Endotoxin-Induced Uveitis in Lewis Rats. , 2003, 44, 1178.		24
110	Simple determination of riluzole in rat brain by high-performance liquid chromatography and spectrophotometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 817, 331-334.	2.3	24
111	Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 Receptor Blockade. Frontiers in Pharmacology, 2017, 8, 710.	3.5	24
112	Effects of Sodium Naproxen Eye Drops on Rabbit Ocular Inflammation Induced by Sodium Arachidonate. Journal of Ocular Pharmacology and Therapeutics, 1991, 7, 125-133.	1.4	23
113	Ocular Pharmacokinetics Profile of Different Indomethacin Topical Formulations. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 571-576.	1.4	23
114	Lipoprotein(a) Serum Levels in Diabetic Patients with Retinopathy. BioMed Research International, 2013, 2013, 1-5.	1.9	23
115	Attenuation of High Glucose-Induced Damage in RPE Cells through p38 MAPK Signaling Pathway Inhibition. Frontiers in Pharmacology, 2021, 12, 684680.	3.5	22
116	A novel adamantane derivative attenuates retinal ischemia $\hat{\epsilon}$ reperfusion damage in the rat retina through $l f 1$ receptors. European Journal of Pharmacology, 2006, 536, 200-203.	3.5	20
117	Effects of novel hybrids of caffeic acid phenethyl ester and NSAIDs on experimental ocular inflammation. European Journal of Pharmacology, 2015, 752, 78-83.	3.5	20
118	NAP modulates hyperglycemic–inflammatory event of diabetic retina by counteracting outer blood retinal barrier damage. Journal of Cellular Physiology, 2019, 234, 5230-5240.	4.1	20
119	Circulating miRNAs in diabetic retinopathy patients: Prognostic markers or pharmacological targets?. Biochemical Pharmacology, 2021, 186, 114473.	4.4	19
120	Effects of Hyaluronan on Free-Radical Formation, Corneal Endothelium Damage, and Inflammation Parameters After Phacoemulsification in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2004, 20, 151-157.	1.4	18
121	Neuroactive steroids protect retinal pigment epithelium against oxidative stress. NeuroReport, 2005, 16, 1203-1207.	1.2	18
122	Possible involvement of nitric oxide in morphine-induced miosis and reduction of intraocular pressure in rabbits. European Journal of Pharmacology, 2006, 534, 227-232.	3.5	18
123	Morphine-Induced Ocular Hypotension Is Modulated by Nitric Oxide and Carbon Monoxide: Role of \hat{l}_4 < sub>3 < l sub>Receptors. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 31-36.	1.4	18
124	Effects of Topical Fucosyl-Lactose, a Milk Oligosaccharide, on Dry Eye Model: An Example of Nutraceutical Candidate. Frontiers in Pharmacology, 2015, 6, 280.	3.5	18
125	Dopaminergic-GABAergic interplay and alcohol binge drinking. Pharmacological Research, 2019, 141, 384-391.	7.1	18
126	Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice. Frontiers in Pharmacology, 2021, 12, 720345.	3.5	18

#	Article	IF	Citations
127	Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Molecular Vision, 2011, 17, 3208-23.	1.1	18
128	Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries. Frontiers in Pharmacology, 2017, 8, 480.	3.5	17
129	Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review. Frontiers in Pharmacology, 2020, 11, 572168.	3.5	17
130	Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor. International Journal of Molecular Sciences, 2020, 21, 9305.	4.1	17
131	Lipid Nanoparticles Traverse Non-Corneal Path to Reach the Posterior Eye Segment: In Vivo Evidence. Molecules, 2021, 26, 4673.	3.8	17
132	$1\hat{l}\pm,25$ -dihydroxyvitamin D3 protects retinal ganglion cells in glaucomatous mice. Journal of Neuroinflammation, 2021, 18, 206.	7.2	17
133	New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review. Biomedicines, 2021, 9, 1311.	3.2	17
134	Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells. Biochemical Pharmacology, 2013, 85, 551-559.	4.4	16
135	Regulation of intraocular pressure in mice: Structural analysis of dopaminergic and serotonergic systems in response to cabergoline. Biochemical Pharmacology, 2013, 86, 1347-1356.	4.4	16
136	Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease. Cell Death and Disease, 2021, 12, 905.	6.3	16
137	Therapeutic potential of nitric oxide modulation in ocular diseases. Drug News and Perspectives, 2010, 23, 430.	1.5	15
138	Hemin, an Inducer of Heme Oxygenase-1, Lowers Intraocular Pressure in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 232-239.	1.4	14
139	Behavioural and neurochemical changes induced by stress-related conditions are counteracted by the neurokinin-2 receptor antagonist saredutant. International Journal of Neuropsychopharmacology, 2013, 16, 813-823.	2.1	14
140	Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents. Future Medicinal Chemistry, 2019, 11, 1523-1536.	2.3	13
141	Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Frontiers in Pharmacology, 2021, 12, 718902.	3.5	13
142	Molecular Dynamics Simulation Techniques as Tools in Drug Discovery and Pharmacology: A Focus on Allosteric Drugs. Methods in Molecular Biology, 2021, 2253, 245-254.	0.9	13
143	Ocular Surface Changes in Type 1 Diabetic Patients. Advances in Experimental Medicine and Biology, 2002, 506, 667-672.	1.6	13
144	Resolvin D1 attenuates the inflammatory process in mouse model of LPSâ€induced keratitis. Journal of Cellular and Molecular Medicine, 2020, 24, 12298-12307.	3.6	12

#	Article	IF	CITATIONS
145	Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye. International Journal of Molecular Sciences, 2021, 22, 4404.	4.1	12
146	Short-and Long-Term Expression of Vegf: A Temporal Regulation of a Key Factor in Diabetic Retinopathy. Frontiers in Pharmacology, 2021, 12, 707909.	3.5	12
147	The P2X7 receptor as a new pharmacological target for retinal diseases. Biochemical Pharmacology, 2022, 198, 114942.	4.4	12
148	Hydroxyl Radical Scavenging Activity of a New Ophthalmic Viscosurgical Device. Current Eye Research, 2007, 32, 105-111.	1.5	11
149	Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor. Biomedical Chromatography, 2002, 16, 274-276.	1.7	10
150	Focus on molecules: Heme oxygenase-1. Experimental Eye Research, 2009, 89, 822-823.	2.6	10
151	Isolation, cultivation, and characterization of primary bovine cochlear pericytes: A new in vitro model of stria vascularis. Journal of Cellular Physiology, 2019, 234, 1978-1986.	4.1	10
152	Epiretinal Membrane Vitrectomy With and Without Intraoperative Intravitreal Dexamethasone Implant: A Systematic Review With Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 635101.	3.5	10
153	Caffeine Protects Against Retinal Inflammation. Frontiers in Pharmacology, 2021, 12, 824885.	3.5	10
154	Pharmacological Evaluation of a New Timolol/Pilocarpine Formulation. Ophthalmic Research, 1998, 30, 101-106.	1.9	9
155	Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure. International Journal of Molecular Sciences, 2020, 21, 9541.	4.1	9
156	Effects of protein-protein interface disruptors at the ligand of the glucocorticoid-induced tumor necrosis factor receptor-related gene (GITR). Biochemical Pharmacology, 2020, 178, 114110.	4.4	9
157	Activity-Dependent Neuroprotective Protein (ADNP)-Derived Peptide (NAP) Counteracts UV-B Radiation-Induced ROS Formation in Corneal Epithelium. Antioxidants, 2022, 11, 128.	5.1	9
158	Pharmacological Evaluation of Anti-Inflammatory Pyrrole-Acetic Acid Derivative Eye Drops. Journal of Ocular Pharmacology and Therapeutics, 1997, 13, 353-361.	1.4	8
159	Neuroactive Steroids Protect Retinal Tissue through ?1Receptors. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 214-216.	2.5	8
160	Effect of Sodium Naproxen on Inflammatory Response Induced by Anterior Chamber Paracentesis in the Rabbit. Journal of Pharmacy and Pharmacology, 2011, 47, 708-712.	2.4	8
161	New Brilliant Blue G Derivative as Pharmacological Tool in Retinal Surgery. Frontiers in Pharmacology, 2020, 11, 708.	3.5	8
162	Pain Following the Use of Anesthesia Formulation Among Individuals Undergoing Cataract Surgery: A Randomized Controlled Trial. Frontiers in Pharmacology, 2020, 11, 440.	3.5	8

#	Article	IF	CITATIONS
163	Metal fume fever. Lancet, The, 2013, 381, 2298.	13.7	7
164	Intravitreal Triamcinolone Acetonide in the Treatment of Ophthalmic Inflammatory Diseases with Macular Edema: A Meta-Analysis Study. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 228-240.	1.4	7
165	Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7. Scientific Reports, 2020, 10, 3972.	3.3	7
166	Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration. Frontiers in Pharmacology, 2021, 12, 656774.	3.5	7
167	Effects of Vitamin D3 and Meso-Zeaxanthin on Human Retinal Pigmented Epithelial Cells in Three Integrated in vitro Paradigms of Age-Related Macular Degeneration. Frontiers in Pharmacology, 2021, 12, 778165.	3.5	7
168	Development and validation of an RP-HPLC-UV method for the determination of BOL-303225-A, a new coumarin-based anti-inflammatory drug, in rat plasma. Biomedical Chromatography, 2007, 21, 351-355.	1.7	6
169	New coumarin-based anti-inflammatory drug: putative antagonist of the integrins $\hat{l}\pm L\hat{l}^22$ and $\hat{l}\pm M\hat{l}^22$. Journal of Pharmacy and Pharmacology, 2010, 60, 1473-1479.	2.4	6
170	Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011. Pharmacoepidemiology and Drug Safety, 2012, 21, 1190-1196.	1.9	6
171	LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY. Retina, 2019, 39, 2107-2115.	1.7	6
172	Glucose-Impaired Corneal Re-Epithelialization Is Promoted by a Novel Derivate of Dimethyl Fumarate. Antioxidants, 2021, 10, 831.	5.1	6
173	Do Extracellular RNAs Provide Insight into Uveal Melanoma Biology?. Cancers, 2021, 13, 5919.	3.7	6
174	Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study. Frontiers in Pharmacology, 2022, 13, 832448.	3.5	6
175	Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 767, 153-158.	2.3	5
176	Effects of Mipragoside® on Ocular Allergic Inflammation in the Rabbit. Journal of Ocular Pharmacology and Therapeutics, 1993, 9, 321-332.	1.4	3
177	Pharmacological Profile of Oxaprozin Eye Drops. Journal of Ocular Pharmacology and Therapeutics, 2002, 18, 75-81.	1.4	2
178	Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta. Biomolecules, 2021, 11, 418.	4.0	2
179	Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats. , 2012, 84, 88-88.		1
180	Editorial: Ocular Pharmacology: Recent Breakthroughs and Unmet Needs. Frontiers in Pharmacology, 2022, 13, 848332.	3.5	1

#	Article	IF	CITATIONS
181	Pituitary Adenylate Cyclase-Activating Polypeptide Protects Corneal Epithelial Cells against UV-B-Induced Apoptosis via ROS/JNK Pathway Inhibition. Applied Sciences (Switzerland), 2022, 12, 3435.	2.5	1
182	Editorial: Chronic Inflammation and Neurodegeneration in Retinal Disease, Volume II. Frontiers in Pharmacology, 0, 13 , .	3.5	1
183	Retinal and Systemic Pharmacokinetics of the Anti-Inflammatory Drug Cloricromene Following Oral Administration in the Rat and Rabbit. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 257-263.	1.4	O
184	Potential drug mechanism(s) targeting the contractile status of hepatic stellate cells. Frontiers in Pharmacology, 2012, 3, 187.	3. 5	0
185	Ocular pharmacology: Cinderella becomes the queen. European Journal of Pharmacology, 2016, 787, 1.	3.5	0
186	Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing Molecules. , 2019, , 333-334.		0